Skip to main content
. 2014 Jan 16;124(2):812–823. doi: 10.1172/JCI66776

Figure 6. Anti-EGFR mAbs reduce outgrowth of C26-hEGFR liver metastases.

Figure 6

(A–D) Kupffer cell–dependent phagocytosis of tumor cells in sinusoids of the liver 1 day after inoculation. Representative images of livers (A) in mice receiving vehicle or (B and D) anti-EGFR mAb–opsonized C26-hEGFR cells and (D) in Kupffer cell–depleted mice. (C) Number of phagocytosed tumor cells per field of view in livers of mice that received vehicle or anti-EGFR mAb–opsonized C26-hEGFR cells. (E–H) Reduced formation of micrometastases and outgrowth in the livers of mice is Kupffer cell dependent. (E and F) Representative images from livers of (E) control or (F) Kupffer cell–depleted mice, which received anti-hEGFR mAb–opsonized C26-hEGFR cells, 4 days after injection of tumor cells. (G and H) Area and number of micrometastases in livers of control or Kupffer cell–depleted mice, which were either injected with vehicle or anti-EGFR mAb–coated tumor cells. Arrowheads indicate uptake of tumor cells by Kupffer cells. Blue, F4/80+ Kupffer cells; red, C26-hEGFR-DiI; green, CD31. Scale bar: 50 mm. **P < 0.01, ***P < 0.001 vehicle vs. anti-EGFR mAbs.